Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Dravet Syndrome Emerging drugs
Dravet Syndrome Emerging Drugs
- ZX008 by Zogenix
- Soticlestat by Ovid Therapeutics
- Ataluren by PTC Therapeutics
Dravet Syndrome Marketed Drugs
- Diacomit by Biocodex
- Epidiolex by GW Pharmaceuticals
Companies have shifted their focus on the development of second-generation therapeutics that follow the step of the most advanced cannabidiol formulation (Epidiolex) and the most advanced serotonergic drug (Fintepla). Most of these compounds would have the potential to treat other forms of epilepsy and are expected to hit Dravet Syndrome market during the forecast period of 2020–2030.
1. Report Introduction
2. Dravet Syndrome
2.1. Overview
2.2. History
2.3. Dravet Syndrome Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Dravet Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. Dravet Syndrome Current Treatment Patterns
3.1. Dravet Syndrome Treatment Guidelines
4. Dravet Syndrome - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Dravet Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Dravet Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Dravet Syndrome Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Dravet Syndrome Late Stage Products (Phase-III)
7. Dravet Syndrome Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dravet Syndrome Discontinued Products
13. Dravet Syndrome Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Dravet Syndrome Key Companies
15. Dravet Syndrome Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Dravet Syndrome Unmet Needs
18. Dravet Syndrome Future Perspectives
19. Dravet Syndrome Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email:Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
